To determine if the clinical: molecular primary tumor subtype incongruent rate in metastatic breast cancer is greater than 15% (Objective 1a) and whether the results of a clinical RNA-based molecular subtyping assay alters treatment plans as perceived by the treating physician in at least 10% of metastatic breast cancer patients
If you choose to take part in this study, some tumor tissue previously removed for standard of care purposes will be used for research. This study does not require a new biopsy. You will also be asked to provide blood samples during treatment visits. The amount of time needed is about 30 minutes at the time of consent. You may leave the study at any time.
100% Remote (online, phone, text)
Lisa Carey
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Breast)
18-1352